Literature DB >> 3919923

Biologic basis for altered fractionation schemes.

H R Withers.   

Abstract

Conventional is commonly not universally correct, and so with dose fractionation in radiotherapy. Fractionation spares slowly responding tissues more than tissues and tumors that show an early response, suggesting that therapeutic gains may be further increased by reducing fractional doses below 1.8 to 2 Gy. The overall duration of a course of radiotherapy should not be the same for all tumors in all sites because the time of onset of regeneration after the start of radiotherapy varies from tissue to tissue and among tumors. Although growth kinetics and dose-response characteristics are known to vary, inability to identify and quantify them prospectively frustrates rational selection of patients for individualized fractionation regimens. In general, curative radiotherapy should be delivered in as short an overall time as possible using the smallest practical dose per fraction. Although 2 Gy, 5 times per week may be a reasonable "average" treatment, greater individualization should be a research goal.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3919923     DOI: 10.1002/1097-0142(19850501)55:9+<2086::aid-cncr2820551409>3.0.co;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  44 in total

Review 1.  Altered fractionation in the treatment of head and neck cancer.

Authors:  K S Hu; L B Harrison
Journal:  Curr Oncol Rep       Date:  1999       Impact factor: 5.075

Review 2.  Endocrine sequelae of cancer therapy in childhood.

Authors:  F B Diamond; B B Bercu
Journal:  J Endocrinol Invest       Date:  2001-10       Impact factor: 4.256

Review 3.  The impact on oncology of the interaction of radiation therapy and radiobiology.

Authors:  Vicente Pedraza Muriel
Journal:  Clin Transl Oncol       Date:  2006-02       Impact factor: 3.405

4.  Comparison of isoeffect relationships in radiotherapy.

Authors:  E O Voit; P N Yi
Journal:  Bull Math Biol       Date:  1990       Impact factor: 1.758

Review 5.  Salvage Re-irradiation Options in Adult Medulloblastoma: A Case Report and Review of the Literature.

Authors:  Francesco Cuccia; Gianluca Mortellaro; Lucia Ognibene; Giuseppe Craparo; Antonio Lo Casto; Giuseppe Ferrera
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 6.  Radiotherapy update.

Authors:  A Horwich
Journal:  BMJ       Date:  1992-06-13

7.  Altered and conventional fractionated radiotherapy in locoregional control and survival of patients with squamous cell carcinoma of the larynx, oropharynx, and hypopharynx.

Authors:  Valentina Krstevska; Simonida Crvenkova
Journal:  Croat Med J       Date:  2006-02       Impact factor: 1.351

8.  Final results of a phase II single-institutional trial with hyperfractionated radiation therapy (HFX) and four-weekly continuous cisplatin in locally advanced head and neck carcinoma.

Authors:  F Arias; G Asín; M I Uzcanga; E Maraví; I Quílez; V Chicata; C Eito; A Viudez; I Hernández; F Mañeru; M A Domínguez
Journal:  Clin Transl Oncol       Date:  2013-11-08       Impact factor: 3.405

9.  NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.

Authors:  Arif N Ali; Peixin Zhang; W K Alfred Yung; Yuhchyau Chen; Benjamin Movsas; Raul C Urtasun; Christopher U Jones; Kwang N Choi; Jeff M Michalski; A Jennifer Fischbach; Arnold M Markoe; Christopher J Schultz; Marta Penas-Prado; Madhur K Garg; Alan C Hartford; Harold E Kim; Minhee Won; Walter J Curran
Journal:  J Neurooncol       Date:  2018-02-05       Impact factor: 4.130

10.  Clinical radiobiology of head and neck cancer: the hypothesis of stem cell activation.

Authors:  P Pedicini; R Caivano; A Fiorentino; L Strigari
Journal:  Clin Transl Oncol       Date:  2014-12-09       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.